Jazz Pharmaceuticals PLC
- BID
219.4
- ASK
219.8
- 91 Units70 Units
- 07/22, 21:59:59 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
121.69%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-5.18 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 219.3 G | 0 Units |
| PRICE DETERMINATION TIME | 07/22/2026 / 09:56:29 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 224.9 | 218.3 |
| PREV. DAY'S PRICE | 223 | (07/21) |
| CHANGE DAY BEFORE | -3.70 | -1.66 % |
| 52 WEEK HIGH / LOW | 224.9 (07/22) | 89.68 (08/07) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 5.64 | 8.00 | -5.18 | 22.21 | 22.79 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 20.16 | 14.24 | 20.29(e) | 10.04 | 9.78 |
PRICE - BOOK RATIO | 2.05 | 1.82 | 2.42 | - | - |
PRICE - SALES RATIO | 2.31 | 2.00 | 2.43 | - | - |
PRICE - CASH FLOW RATIO | 8.12 | 5.82 | 7.65 | - | - |
Master Data
| WKN | A1JS1K |
| ISIN | IE00B4Q5ZN47 |
| SYMBOL | J7Z |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | JAZZ PHARMACEUT. DL-,0001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 4.88 % | 11.15 % | 27.31 % | 50.83 % | 121.69 % | 92.88 % | 48.58 % | 53.46 % |
| HIGH | 224.90 | 224.90 | 224.90 | 224.90 | 224.90 | 224.90 | 224.90 | 224.90 |
| LOW | 204.60 | 193.00 | 165.00 | 134.35 | 89.68 | 86.36 | 86.36 | 134.35 |
Dividende
pro Aktie
JAZZ PHARMACEUT. DL-,0001 does not deliver dividend information
Company profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Structured products for Jazz Pharmaceuticals PLC
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.